Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Hiding in Plain Sight: The Neuro-Protective Benefit of Tropomyosin Receptor Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers": Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 Targets.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Impact of concurrent colonic CMV infection on clinical outcomes in immune checkpoint inhibitor-induced colitis.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Renal medullary carcinoma: a systematic review of clinical and radiological findings.

International urology and nephrology·2026
Same author

Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer.

Radiology·2026
Same author

Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304).

European urology oncology·2026
Same author

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Cancer·2025

Related Experiment Video

Updated: Mar 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

New developments in metastatic prostate cancer therapy.

Thubeena Manickavasagar, Clare Gilson, Simon Chowdhury

    The Practitioner
    |November 5, 2015
    PubMed
    Summary

    Metastatic prostate cancer remains a lethal condition, with limited survival for advanced cases. Androgen deprivation therapy is standard, but resistance develops, necessitating treatments like Radium-223 for bone metastases.

    Area of Science:

    • Oncology
    • Radiopharmaceutical Therapy

    Background:

    • Metastatic prostate cancer is a significant cause of mortality.
    • Current treatments like androgen deprivation therapy (ADT) eventually lead to resistance.
    • Bone metastases are prevalent in castrate-refractory prostate cancer.

    Purpose of the Study:

    • To review the role of Radium-223 dichloride in managing metastatic castrate-refractory prostate cancer.
    • To highlight Radium-223's mechanism of action and targeted delivery to bone metastases.

    Main Methods:

    • Review of current treatment guidelines and clinical data for advanced prostate cancer.
    • Focus on the efficacy and indication of Radium-223 dichloride.
    • Discussion of androgen deprivation therapy (ADT) and chemotherapy resistance.

    More Related Videos

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    1.1K
    Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
    07:01

    Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

    Published on: August 29, 2016

    15.3K

    Related Experiment Videos

    Last Updated: Mar 30, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    14.0K
    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    1.1K
    Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
    07:01

    Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

    Published on: August 29, 2016

    15.3K

    Main Results:

    • ADT is the gold standard for advanced prostate cancer but resistance is common.
    • Docetaxel is a first-line chemotherapy for symptomatic metastatic castrate-refractory prostate cancer.
    • Radium-223 dichloride targets bone metastases in patients with symptomatic disease and no visceral metastases.

    Conclusions:

    • Radium-223 dichloride offers a targeted therapeutic option for bone metastases in castrate-refractory prostate cancer.
    • Management of advanced prostate cancer requires strategies to overcome ADT resistance.
    • Early detection and targeted therapies are crucial for improving outcomes.